A study to investigate the pharmacokinetics and safety of dupilumab in participants ≥2 years to <12 years of age with uncontrolled chronic spontaneous urticaria (CSU) (LIBERTY-CSU CUPIDKids)

Trial Identifier: PKM16982
Sponsor: Sanofi
Start Date: August 2022
Primary Completion Date: November 2024
Study Completion Date: February 2025
Condition: Urticaria

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Canada, Ontario Hamilton, Ontario, Canada, L8S1G5
Canada, Quebec Montreal, Quebec, Canada, H4A 3J1
CANADA, Alberta Calgary, Alberta, CANADA, T2W 4X9
CANADA, Alberta Edmonton, Alberta, CANADA, T5J 3S9
Japan, Kanagawa Yokohama-shi, Kanagawa, Japan, 232-8555
Japan, Mie Tsu-shi, Mie, Japan, 514-0125
United States, Idaho Boise, Idaho, United States, 83706
United States, Missouri St Louis, Missouri, United States, 63110
United States, New York New York, United States, 10032
United States, Ohio Akron, Ohio, United States, 44308
United States, Ohio Cincinnati, Ohio, United States, 45229-3026
United States, Oklahoma Tulsa, Oklahoma, United States, 74136
United States, Tennessee Nashville, Tennessee, United States, 37232
UNITED STATES, Florida Coral Gables, Florida, UNITED STATES, 33146
UNITED STATES, New York Hawthorne, New York, UNITED STATES, 10532